Akari Therapeutics (AKTX) Receivables - Net (2011 - 2013)

Akari Therapeutics (AKTX) has reported Receivables - Net for 3 consecutive years, with $6000.0 the latest figure, recorded in Q4 2013.

• Quarterly Receivables - Net fell 50.0% year-over-year to $6000.0 in Q4 2013, while the trailing twelve-month figure through Dec 2013 was $6000.0 (down 50.0% YoY) and the FY2013 annual result came in at $6000.0, down 50.0% from the prior year.
• Receivables - Net retreated to $6000.0 in Q4 2013 per AKTX's latest filing, from $12000.0 in the prior quarter.
• Over the last five years, Receivables - Net for AKTX reached as high as $19000.0 in Q4 2011 and fell as low as $6000.0 in Q4 2013.
• A 3-year average of $12333.3 and a median of $12000.0 in 2012 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2012 — Receivables - Net sank 36.84% — and 2013, when it plunged 50.0%.
• Year by year, Receivables - Net stood at $19000.0 in 2011, then slumped by 36.84% to $12000.0 in 2012, then tumbled by 50.0% to $6000.0 in 2013.
• According to Business Quant data, Receivables - Net over the past three periods registered $6000.0, $12000.0, and $19000.0 for Q4 2013, Q4 2012, and Q4 2011 respectively.